Efficacy and tolerability of pregabalin in partial epilepsy

Expert Review of Neurotherapeutics

Volumn 8, Issue 7, 2008, Pages 1013-1024

  Beydoun, Ahmad ^a   Nasreddine, Wassim ^a   Atweh, Samir ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Antiepileptic drug; GABA; Pregabalin

Indexed keywords

4 AMINOBUTYRIC ACID; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; OXCARBAZEPINE; OXYCODONE; PHENYTOIN; PLACEBO; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VOLTAGE GATED CALCIUM CHANNEL; ZONISAMIDE;

ARTICLE; ASTHENIA; ATAXIA; BLURRED VISION; CLINICAL TRIAL; COGNITIVE DEFECT; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTRIC SHOCK; FOCAL EPILEPSY; GABAERGIC SYSTEM; GRAND MAL SEIZURE; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MOTOR COORDINATION; MOTOR DYSFUNCTION; NEUROTRANSMISSION; NONHUMAN; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRESYNAPTIC NERVE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIDE EFFECT; SOMNOLENCE; STEADY STATE; TONIC CLONIC SEIZURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VERTIGO; WEIGHT GAIN;

ANTICONVULSANTS; DRUG EVALUATION; EPILEPSIES, PARTIAL; GAMMA-AMINOBUTYRIC ACID; HUMANS;

EID: 46949093712     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.7.1013     Document Type: Article

References (56)

1. Dworkin RHP, Corbin AEM, Young JPJ et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60, 1274-1283 (2003).
2. Sabatowski R, Galvez R, Cherry DA et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with postherpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109, 26-35 (2004).
3. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110, 628-638 (2004).
4. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J. Pain 6, 253-260 (2005).
5. Crofford LJ, Rowbotham MC, Mease PJ et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arth. Rheumatol. 52, 1264-1273 (2005).
6. Feltner DE, Crockatt JG, Dubovsky SJ et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 23, 240-249 (2003).
7. Pande AC, Feltner DE, Jefferson JW et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder a placebo-controlled, multicenter study.J. Clin. Psychopharmacol. 24, 141-149 (2004).
8. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder double-blind, placebo-controlled comparison of BID versus TID dosing. J. Clin. Psychopharmacol. 25, 151-158 (2005).
9. Kwan P, Brodie M. Effectiveness of first antiepileptic drug. Epilepsia 42(10), 1255-1260 (2001).
10. Kwan P, Brodie M. Early identification of refractory epilepsy. N. Engl. J. Med. 342, 314-319 (2000).
11. Ben-Menachem E. Pregbalin pharmacology and its relevance to clinical practice. Epilepsia 45(Suppl. 6), 13-18 (2004).
12. Yuen PW, Kanter GD, Taylor CP, Vartanian MG. Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant. Bioorg. Med. Chem. Lett. 4, 823-826 (2003).
13. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: The calcium channel (α2-δ (α2-δ) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 73, 137-150 (2007).
14. Silverman RB, Andruszkiewicz R, Nanavati SM, Taylor CP, Vartanian MG. G. 3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase. J. Med. Chem. 34, 2295-2298 (1991).
15. Errante LD, Petroff OAC. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 12, 300-306 (2003).
16. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 51 (1-2), 31-71 (2002).
17. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the a2d subunit of a calcium channel. J. Biol. Chem. 271, 5768-5776 (1996).
18. Sills JG. The mechanisms of action of gabapentin and pregabalin. Curr. Opin. Pharmacol. 6, 108-113 (2006).
19. Millan MJ. The neurobiology and control of anxious states. Prog. Neurobiol. 70, 83-244 (2003).
20. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [3H] norepinephrine release from rat neocortical slices by gabapentin and pregabalin.J. Pharmacol. Exp. Ther. 295, 1086-1093 (2000).
21. +-evoked release of [3H] glutamate from rat caudal trigeminal nucleus slices. Pain 93, 191-196 (2001).
22. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42, 229-236 (2002).
23. Stahl SM. Mechanism of action of (α2δ ligands: voltage sensitive calcium channel (VSCC) modulators. J. Clin. Psychiatry 65(8), 1033-1034 (2004).
24. Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RSG. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur. J. Neurosci. 20, 1566-1576 (2004).
25. Coderre, TJ, Kumar N, Lefebvre CD, Yu JSC. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J. Neurochem. 94, 1131-1139 (2005).
26. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105, 133-144 (2003).
27. Bian F, Li Z, Offord JD et al. Calcium channel α2-δ Type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in α2-δ Type 1 genetically modified mice. Brain Res. 1075, 68-80 (2006).
28. Field MJ, Cox PJ, Stott E et al. Identification of the α2-δ-1 subunit of voltage dependent calcium channels as a novel molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl Acad. Sci. USA 103, 17537-17542 (2006).
29. Lang N, Sueske E, Hasan A, Paulus W, Tergau F. Pregabalin exerts oppositional effects on different inhibitory circuits in human motor cortex: a double-blind, placebo-controlled transcranial magnetic stimulation study. Epilepsia 47(5), 813-819 (2006).
30. Huang CW, Huang CC, Wu SN. The opening effect of pregabalin on ATP-sensitive potassium channels in differentiated hippocampal neuron-derived H19-7 cells. Epilepsia 47(4), 720-726 (2006).
31. Su TZ, Feng MR, Weber ML. Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J. Pharmacol. Exp. Ther. 313, 1406-1415 (2005).
32. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res. 10, 276-281 (1993).
33. Radulovic LL, Taylor CP, Walker RM. The preclinical pharmacology, pharmacokinetics and toxicology of gabapentin. Med. Actual. 31, 597-611 (1995).
34. Bockbrader HN, Hunt T, Strand JC, Posvar EL, Sedman A. Pregabalin pharmacokinetics and safety in healthy volunteers: results from two Phase 1 studies. Neurology 54(Suppl. 3), A421 (2000).
35. Kugler AR, Robbins JL, Strand JC et al. Pregabalin overview: a novel CNS-active compound with anticonvulsant activity. Poster presented at: The Annual Meeting of the American Epilepsy Society, Seattle, WA, USA, 6-11 December 2002.
36. Berry D, Millington C. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC. Ther. Drug Monit. 27, 451-456 (2005).
37. Brodie MJ, Wilson EA, Wesche DL et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 46(9), 1407-1413 (2005).
38. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol. 43, 277-283 (2003).
39. Corrigan BW, Pool WF, Posvar EL. Metabolic disposition of pregabalin in healthy volunteers [abstract no. PI-68]. Clin. Pharmacol. Ther. 69, P18 (2001).
40. Loescher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2, 145-181 (1988).
41. Vartanian MG, Radulovic LL, Kinsora JJ et al. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 68, 189-205 (2006).
42. Andre W, Rigoulot MA, Koning E, Ferrandon A, Nehlig A. Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat. Epilepsia 44, 893-903 (2003).
43. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60, 1631-1637 (2003).
44. Arroyo S, Anhut H, Kugler AR et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45, 20-27 (2004).
45. Beydoun A, Uthman BM, Kugler AR et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64, 475-480 (2005).
46. Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 46(12), 1926-1936 (2005).
47. Carreño M, Maestro I, Molins A et al. Pregabalin as add-on therapy for refractory partial seizures in every day clinical practice. Seizure 16(8), 709-712 (2007).
48. Sirven JI, Fife TD, Wingerchuk DM, Drazkowski JF Second-generation antiepileptic drugs' impact on balance: a meta-analysis. Mayo Clin. Proc. 82(1), 40-47 (2007).
49. Ortinski P, Kimford JM. Cognitive side effects of antiepileptic drugs. Epilepsy Behav. 5, 60-65 (2004).
50. Ciesielski AS, Samson S, Steinhoff BJ. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study. Epilepsy Behav. 9(3), 424-431 (2006).
51. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 42(6), 790-792 (2001).
52. Heckmann JG, Ulrich K, Dütsch M, Neundörfer B. Pregabalin associated asterixis. Am. J. Phys. Med. Rehabil. 84(9), 724 (2005).
53. Hitiris N, Barrett JA, Brodie MJ. Erectile dysfunction associated with pregabalin add-on treatment in patients with partial seizures: five case reports. Epilepsy Behav. 8,418-421(2006).
54. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res. 47, 17-25 (2001).
55. Otoul C, Arrigo C, van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin. Neuropharmacol. 28(2), 72-78 (2005).
56. Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 48(7), 1303-1307 (2007).